Abstracts Archive - Page 1468 of 2425 - ACR Meeting Abstracts

Abstract Number: 754 • 2016 ACR/ARHP Annual Meeting
The Duration of Anti-Malarial Agent Intake in the First 5 Years of the Disease and Prognosis in Patients with Systemic Lupus Erythematosus
Rattapol Pakchotanon¹, Dafna D. Gladman², Jiandong Su² and Murray Urowitz³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Anti-malarial agents (AM) prevent damage in patients with systemic lupus erythematosus (SLE). We aimed to examine whether the duration of AM therapy early in…
Abstract Number: 755 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Level Monitoring in a Predominantly Hispanic Systemic Lupus Erythematosus Cohort
James Miceli¹, Kayla Neville¹, Laura Geraldino-Pardilla² and Anca D. Askanase³, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ³Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) is recommended for all patients with SLE. While patient reported adherence rates are between 51-64%, blood HCQ level testing may be a…
Abstract Number: 756 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics and Exposure-Response Relationship of Belimumab Administered Subcutaneously to SLE Patients
Herbert Struemper¹, Mita Thapar², David Gordon³ and David Roth³, ¹Quantitative Clinical Development, PAREXEL, Durham, NC, ²ICON, Marlow, United Kingdom, ³GSK, Philadelphia, PA
Background/Purpose: Monthly (q4w) intravenously (IV) administered belimumab 10 mg/kg is approved for the treatment of adults with active, autoantibody-positive SLE receiving standard therapy. The present…
Abstract Number: 757 • 2016 ACR/ARHP Annual Meeting
Measures of Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE): Results from a Two-Part 52 Week Pilot Study of Repository Corticotropin Injection (H.P. Acthar® Gel)
Richard A. Furie¹, Margaret Mitrane², Enxu Zhao³ and Patrice Becker⁴, ¹Division of Rheumatology, North Shore LIJ Health System, Great Neck, NY, ²Manhattan BioPharm Consultants, New York, NY, ³Research and Development; Biometrics, Mallinckrodt Pharmaceuticals, Ellicott City, MD, ⁴Research & Development, Mallinckrodt Pharmaceuticals, Ellicott City, MD
Background/Purpose: Multiple outcome measures have been utilized in SLE clinical trials. Consistency of response assessed by different instruments enhances confidence in the efficacy of pharmacologic…
Abstract Number: 758 • 2016 ACR/ARHP Annual Meeting
Relationship Between Corticosteroids and Adverse Events in SLE –Data from the Clinical Trial Belimumab in Subjects with Systemic Lupus Erythematosus
Sharzad Emamikia¹, Cidem Gentline², Magnus Backheden³, Katerina Chatzidionysiou², Laurent Arnaud⁴ and Ronald F. van Vollenhoven^2,5, ¹Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Department of Learning, Informatics, Management and Ethics, Unit for Medical Statistics, Stockholm, Sweden, ⁴Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Dept. of Medicine, Karolinska institutet, Stockholm, Sweden, ⁵Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Corticosteroids (CSs) are widely used in Systemic Lupus Erythematosus (SLE) patients, but have side-effects when used for prolonged periods of time. Our aim was…
Abstract Number: 759 • 2016 ACR/ARHP Annual Meeting
Gene Signature for Glucocorticoid, from in Vitro to In Vivo
Yanhua Sarah Hu¹, Somnath Bandyopadhyay¹, Deborah Furst¹, A Johnsen¹, Robert Latek¹, Steven G. Nadler² and Julie Carman³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ, ³Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Steroids are widely used in clinical practice for treating systemic lupus erythematosus (SLE), and can have a strong effect on immune cells in Whole…
Abstract Number: 760 • 2016 ACR/ARHP Annual Meeting
Effects of Type I Interferon Inhibition on Blood Leukocyte Subsets in Patients Treated in a Phase IIb Clinical Study of Anifrolumab in SLE
Geoffrey Stephens¹, Rong Zeng², Xiang Guo², Steve Eck³, Yuling Wu³, Liangwei Wang³, Gabor Illei³ and Wendy White², ¹Cellcion, Clarksburg, MD, ²Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ³MedImmune, LLC, Gaithersburg, MD
Background/Purpose: A Phase IIb randomized controlled study (NCT01753193) was conducted with anifrolumab, a fully human, anti-interferon (IFN)–α receptor (IFNAR1) specific antibody in adults with moderate…
Abstract Number: 761 • 2016 ACR/ARHP Annual Meeting
Exposure-Response Analysis for Selection of Optimal Dosage Regimen of Anifrolumab in Patients with Systemic Lupus Erythematosus
L Santiago¹, B Wang², P Brohawn², L Wang², G Illei² and L Roskos², ¹MedImmune, Mountain View, CA, ²MedImmune, Gaithersburg, MD
Background/Purpose: Anifrolumab is a fully human IgG1 monoclonal antibody directed against subunit 1 of the type I interferon–α receptor (IFNAR1) currently in development for the…
Abstract Number: 762 • 2016 ACR/ARHP Annual Meeting
Pragmatic Treatment of Patients with Systemic Lupus Erythematosus with Rituximab: Long-Term Effects on Serum Immunoglobulins
Venkat Reddy¹, Lina Martínez-Estupiñán², David A. Isenberg³, Maria J. Leandro³ and Geraldine Cambridge³, ¹Rheumatology, University College Hospital, London, United Kingdom, ²Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: B cell depletion therapy based on rituximab is a therapeutic option for refractory disease in patients with Systemic Lupus Erythematosus (SLE). Hypogammaglobulinemia can be…
Abstract Number: 763 • 2016 ACR/ARHP Annual Meeting
Rituximab As a Corticosteroid-Sparing Agent in Patients with Systemic Lupus Erythematosus
Na Ri Kim¹, Jung Su Eun¹, Jong Wan Kang¹, Eon Jeong Nam¹ and Young Mo Kang², ¹Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of
Background/Purpose : The treatment of active systemic lupus erythematosus (SLE) remains problematic because the current treatment regimen based on corticosteroids and immunosuppressive agents have significant…
Abstract Number: 764 • 2016 ACR/ARHP Annual Meeting
Atacicept: Integrated Safety Profile from Phase II Randomized Placebo-Controlled Studies in Autoimmune Diseases
Patricia Fraser, Wai Chin and Amy Kao, EMD Serono, Billerica, MA
Background/Purpose: Atacicept, a recombinant fusion protein, targets both BLyS (B lymphocyte stimulator) and APRIL (a proliferation-inducing ligand), B cell activating factors involved in the pathogenesis…
Abstract Number: 765 • 2016 ACR/ARHP Annual Meeting
High Baseline B Lymphocyte Stimulator (BLyS) Levels Predict Response While Smoking and Organ Damage at Baseline Predict Failure to Belimumab in Three Swedish Clinical Practice Settings
Ioannis Parodis¹, Christopher Sjöwall², Andreas Jönsen³, Agneta Zickert¹, Daniel Ramsköld¹, Martina Frodlund², Laurent Arnaud¹, Vivianne Malmström¹, Anders A. Bengtsson³ and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ³Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden
Background/Purpose: Belimumab is a biologic drug approved to treat Systemic Lupus Erythematosus (SLE). The efficacy of belimumab has been demonstrated in phase III clinical trials.…
Abstract Number: 766 • 2016 ACR/ARHP Annual Meeting
Withdrawal of Mycophenolate Mofetil after Maintenance Treatment of SLE Nephritis Associated with Renal Relapse
H. Michael Belmont¹ and Adey Berhanu², ¹New York University School of Medicine, New York, NY, ²Rheumatology Fellowship Program, NYU Langone Medical Center/NYU School of Medicine, New York, NY
Background/Purpose: Current ACR and EULAR evidence based guidelines provide recommendations for therapeutic choices to induce and maintain remission of lupus nephritis, however, the appropriate duration…
Abstract Number: 767 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Induced Retinopathy in SLE
Michelle Petri¹ and Wei Fu², ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Retinal toxicity from hydroxychloroquine (HCQ), has been recognized for many years. But poor compliance of HCQ might confound results of previous studies. Therefore, we…
Abstract Number: 768 • 2016 ACR/ARHP Annual Meeting
7-Year Safety and Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus
Richard A. Furie¹, Daniel J. Wallace², Cynthia Aranow³, James Fettiplace⁴, Barbara Wilson⁵, Prafull Mistry⁶, David A Roth⁷ and David Gordon⁷, ¹Northwell Health, Great Neck, NY, ²Cedars-Sinai Medical Center, UCLA, Los Angeles, CA, ³The Feinstein Institute for Medical Research, Manhasset, NY, ⁴GSK, Uxbridge, Middlesex, United Kingdom, ⁵GSK, Research Triangle Park, NC, ⁶GSK, Stevenage, Hertfordshire, United Kingdom, ⁷GSK, Philadelphia, PA
Background/Purpose: The availability of published long-term data from systemic lupus erythematosus (SLE) clinical trials is limited [1]. To complement existing belimumab data, we examined the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].